The U.S. Food and Drug Administration has approved talazoparib, Pfizer's drug for an advanced form of breast cancer tied to an inherited gene mutation.
The drug is part of a class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.
Talazoparib is a once-daily pill that Pfizer acquired during its acquisition of Medivation in 2016. The drug is indicated for breast cancer triggered by mutation of BRCA genes, which accounts for 25 – 30 percent of hereditary breast cancers and 5 – 10 percent of all breast cancers.
Read the Reuters report